Hydroxychloroquinedrug info

hydroxychloroquine sulfate 200 MG Oral Tablet [Plaquenil]

What it is used for

PLAQUENIL is an antimalarial and antirheumatic indicated for the:

Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients.

Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients.

Treatment of rheumatoid arthritis in adults.

Treatment of systemic lupus erythematosus in adults.

Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: PLAQUENIL is not recommended for the:

Treatment of complicated malaria.

Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species.

Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified.

Prophylaxis of malaria in geographic areas where chloroquine resistance occurs.

Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary.

1.1 Malaria PLAQUENIL is indicated in adult and pediatric patients for the: •

Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale.

Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: PLAQUENIL is not recommended for:

Treatment of complicated malaria.

Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species.

Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified.

Prophylaxis of malaria in geographic areas where chloroquine resistance occurs.

Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. For the most current information about drug resistance, refer to the latest recommendations from the Center for Disease Control and Prevention 1.

1.2 Rheumatoid

Arthritis PLAQUENIL is indicated for the treatment of acute and chronic rheumatoid arthritis in adults.

1.3 Systemic

Lupus Erythematosus PLAQUENIL is indicated for the treatment of systemic lupus erythematosus in adults.

1.4 Chronic

Discoid Lupus Erythematosus PLAQUENIL is indicated for the treatment of chronic discoid lupus erythematosus in adults.

Text above is quoted in full from the FDA-approved drug label published by openFDA, effective April 9, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.

Description

PLAQUENIL (hydroxychloroquine sulfate) is an antimalarial and antirheumatic drug, chemically described as 2-[[4-[(7-Chloro-4- quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1) with the molecular formula C 18 H 26 ClN 3 O

H 2 SO 4. The molecular weight of hydroxychloroquine sulfate is 433.95. Its structural formula is: Hydroxychloroquine sulfate is a white or off-white crystalline powder, freely soluble in water; practically soluble in alcohol, chloroform, and ether. PLAQUENIL (hydroxychloroquine sulfate) tablets for oral administration contain 200 mg hydroxychloroquine sulfate (equivalent to 155 mg of hydroxychloroquine) and the following inactive ingredients: black iron oxide, carnauba wax, corn starch, dibasic calcium phosphate, hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol 400, polysorbate 80, titanium dioxide. chem-formula

Text above is quoted in full from the FDA-approved drug label published by openFDA, effective April 9, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.

This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.

See what it costs — price without insurance